ArticleAMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science2026
Use of Family Relationships in Commercial Claims Data to Characterize Clinical Events of Patients with
Article in AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BRCA1/2 genetic cascade testing has been studied in small-scale survey and controlled settings, but limited large-scale studies have been done because health records don't typically link family members. This study uses commercial claims data that connect family members on the same insurance plan to identify a large cohort of BRCA1/2 proband and cascade testers and characterizes their breast cancer screening and prevention service utilization. We identified 709 proband and 819 cascade testers. Consistent with clinical guidelines to test for a specific BRCA1/2 variant in a family, more cascade testers received known variant tests than proband testers. Also consistent with guidelines, more proband testers received BRCA1/2 testing after a breast cancer diagnosis compared to cascade testers, and more cascade testers had genetic counseling events pre-BRCA1/2 testing compared to proband testers. This technique and large BRCA1/2 genetic cascade testing cohort can open doors for new research.
Identifiers
42317851PMC13274322What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.